BAUSCH HEALTH AMERICAS, INC.
🇺🇸United States
Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-09-14
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 460
- Registration Number
- NCT00529087
A Study Evaluating Intravenous (IV) MOA-728 for the Treatment of Postoperative Ileus (POI) in Participants After Ventral Hernia Repair
- First Posted Date
- 2007-09-14
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 374
- Registration Number
- NCT00528970
- Locations
- 🇰🇷
Kangnam-Gu, Seoul, Korea, Republic of
Study Evaluating Oral MOA-728 in Subjects on Methadone Therapy
Phase 1
Withdrawn
- Conditions
- First Posted Date
- 2007-07-23
- Last Posted Date
- 2019-11-29
- Lead Sponsor
- Bausch Health Americas, Inc.
- Registration Number
- NCT00505583
A Single-Center, Open-Label, Exploratory Study of the Volumizing Effect of SCULPTRA Measured by Three Dimensional Digital Surface Imaging
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-06-18
- Last Posted Date
- 2019-09-18
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT00487474
Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-06-13
- Last Posted Date
- 2019-08-15
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 443
- Registration Number
- NCT00486031
- Locations
- 🇺🇸
Community Clinical Trials, Orange, California, United States
🇺🇸Premeire Pharmaceutical Research, Tempe, Arizona, United States
🇺🇸Digestive and Liver Disease Specialists, Norfolk, Virginia, United States
Study Evaluating the Safety and Tolerability of a New Intravenous Formulation of MOA-728 in Healthy Subjects
Phase 1
Completed
- Conditions
- First Posted Date
- 2007-04-24
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT00464802
Diarrhea Predominant Irritable Bowel Syndrome in Females
- First Posted Date
- 2007-04-18
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT00461526
- Locations
- 🇺🇸
Medical Associates Research Group, San Diego, California, United States
🇺🇸Vital re:Search, Greensboro, North Carolina, United States
🇺🇸Research Solutions Corp., Cincinnati, Ohio, United States
Study Evaluating MOA-728 in Subjects on Stable Methadone Maintenance
Phase 1
Completed
- Conditions
- First Posted Date
- 2007-03-15
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Bausch Health Americas, Inc.
- Registration Number
- NCT00447811
Canadian Aesthetic Experience With Sculptra Therapy
- First Posted Date
- 2007-03-14
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 76
- Registration Number
- NCT00447551
- Locations
- 🇨🇦
Sanofi-Aventis Administrative Office, Québec, Canada
Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV)
- First Posted Date
- 2007-03-12
- Last Posted Date
- 2012-07-27
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 278
- Registration Number
- NCT00446134
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, 8635 W. 3rd Street, Suite 590W, Los Angeles, California, United States
© Copyright 2024. All Rights Reserved by MedPath